Novartis ‘pretty aggressive and active’ in neuroscience BD, gene editing not so much, research chief says
Novartis’ R&D chief Fiona Marshall, Ph.D., says the company has been “pretty aggressive and active” in neuroscience-focused business development, looking for a boost to one of the company’s four key therapeutic pillars.